TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8499205

Group type: EXPERIMENTAL
Intervention: Hudson face mask at 4 litre min‐1 (group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nasal cannulae at 2 litre min‐1 (group II)
Number of subjects: 30
Study: 3304473

Group type: EXPERIMENTAL
Intervention: CHOP regimen (low doses of adriamycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy, radiotherapy, splenectomy, leukapheresis, monoclonal antibodies, immunomodulating agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 0
Study: 31628854

Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ubrogepant 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29120908

Group type: EXPERIMENTAL
Intervention: Thiopurine treatment (discontinuation rate 22% in accepting group)
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Thiopurine treatment (steady-state metabolite levels)
Number of subjects: 767
Study: 25072784

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 7447

Group type: EXPERIMENTAL
Intervention: Waist‐to‐height ratio (WHtR)
Number of subjects: 7447

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 7447

Group type: COMPARATOR
Intervention: PREDIMED intervention
Number of subjects: 7447
Study: 22385415

Group type: EXPERIMENTAL
Intervention: Diclofenac-tramadol combination (diclofenac 100 mg rectal suppository 8 hourly till 24 h + tramadol 75 mg intravenous 6 hourly)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Diclofenac-acetaminophen combination (diclofenac 100 mg rectal suppository 8 hourly till 24 h + acetaminophen 1 g intravenous 6 hourly)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both groups (diclofenac-tramadol and diclofenac-acetaminophen)
Number of subjects: 204
Study: 20820456

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) combined with a coronally advanced flap (CAF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD) combined with a coronally advanced flap (CAF)
Number of subjects: 20
Study: 19040171

Group type: EXPERIMENTAL
Intervention: Care coordination programs with nurse-provided patient education (mostly by telephone), average of two contacts per month.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 15727280

Group type: EXPERIMENTAL
Intervention: Website information provided to the experimental group prior to surgery.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no website information).
Number of subjects: 64
Study: 12845985

Group type: EXPERIMENTAL
Intervention: Continuous portal triad clamping
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intermittent portal triad clamping
Number of subjects: 35
Study: 10378323

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (200 IU dalteparin per kilogram body-weight per 24 hours), firm compression bandages, and encouraged walking
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Compression bandages and compression stockings (in ongoing randomized trial)
Number of subjects: 929
Study: 8927235

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 100 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Corticotropin fragment (ACTH 4-9) 300 micrograms
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 10
Study: 8354332

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (5 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (15 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (30 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (35 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous amino acids (10 g)
Number of subjects: 8
Study: 3545108

Group type: EXPERIMENTAL
Intervention: Methimazole in combination with thyroxine (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metoprolol (Group II)
Number of subjects: 30
Study: 29626233

Group type: EXPERIMENTAL
Intervention: 500 IU of hCG with 40 μL of culture medium injected into the uterus before embryo transfer
Number of subjects: 180

Group type: COMPARATOR
Intervention: 40 μL of culture medium infused into the uterus before embryo transfer (sham control)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No intervention (second control group)
Number of subjects: 180
Study: 27809880

Group type: EXPERIMENTAL
Intervention: Positive training (towards positive and away from negative stimuli)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham training (control condition)
Number of subjects: 126
Study: 25025247

Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 7

Group type: COMPARATOR
Intervention: Non-gum-chewing control
Number of subjects: 7
Study: 22785255

Group type: EXPERIMENTAL
Intervention: Peg‐interferon‐alpha‐2a (PEG‐IFN)
Number of subjects: 40
Study: 20386325

Group type: EXPERIMENTAL
Intervention: Formula+LCP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula
Number of subjects: 0
Study: 18672194

Group type: EXPERIMENTAL
Intervention: PIIINP
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: MMP-1
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: IL-18
Number of subjects: 1009
Study: 16165009

Group type: EXPERIMENTAL
Intervention: Women to Women computer-based intervention
Number of subjects: 63
Study: 12742805

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril and indapamide)
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study: 11106133

Group type: EXPERIMENTAL
Intervention: Fluoxetine 10 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Fluoxetine (both doses)
Number of subjects: 243
Study: 8873505

Group type: EXPERIMENTAL
Intervention: Intranasal nicotine spray
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 19
Study: 1855281

Group type: EXPERIMENTAL
Intervention: 20 mg dexamethasone (i.v.)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7049340

Group type: EXPERIMENTAL
Intervention: Lecithin and linoleic acid supplements
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 22
Study: 31453760

Group type: EXPERIMENTAL
Intervention: Natural directionality mode
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Adaptive directionality mode
Number of subjects: 13

Group type: COMPARATOR
Intervention: Omnidirectional mode
Number of subjects: 13
Study: 28260596

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic hysterectomy (RALH)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 360
Study: 27050347

Group type: EXPERIMENTAL
Intervention: Brinzolamide/timolol (BT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Dorzolamide/timolol (DT)
Number of subjects: 73
Study: 25079862

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Highest HbA1c tertile
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Lowest HbA1c levels
Number of subjects: 489
Study: 22849964

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study: 19039808

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (8-week programme, 2-hour sessions)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 203
Study: 17451577

Group type: EXPERIMENTAL
Intervention: Stacked double pulses (single-pass treatment)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Double-pass treatment of single pulses
Number of subjects: 11
Study: 15170544

Group type: EXPERIMENTAL
Intervention: Division of the pulmonary ligament
Number of subjects: 35

Group type: COMPARATOR
Intervention: Preservation of the pulmonary ligament
Number of subjects: 35
Study: 11641361

Group type: COMPARATOR
Intervention: Technegas inhalation during tidal breathing
Number of subjects: 11

Group type: COMPARATOR
Intervention: Inhaled methacholine (dose sufficient to abolish expiratory flow reserve)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Three increasing doses of methacholine
Number of subjects: 11
Study: 9689551

Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetes mellitus patients with microalbuminuria
Number of subjects: 132

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 132

Group type: COMPARATOR
Intervention: Normoalbuminuric diabetics
Number of subjects: 132
Study: 7737258

Group type: EXPERIMENTAL
Intervention: Casodex (ICI 176,334) 50 mg/day
Number of subjects: 267

Group type: COMPARATOR
Intervention: Castration (either medical or surgical)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Casodex (100 and 150 mg/day)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Casodex (50 mg/day)
Number of subjects: 267
Study: 2512366

Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 77092

Group type: COMPARATOR
Intervention: Not invited to screening (control)
Number of subjects: 77092
Study: 134897

Group type: EXPERIMENTAL
Intervention: Alprenolol 400 mg daily
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study: 30673056

Group type: EXPERIMENTAL
Intervention: Somatization tendencies (ST) in adolescents
Number of subjects: 11153

Group type: EXPERIMENTAL
Intervention: Somatic symptoms score (SSS)
Number of subjects: 11153

Group type: EXPERIMENTAL
Intervention: Family medical history, anxiety and depression scores, superstitious beliefs, left‐behind adolescents, teacher‐student support, family conflict, family independence and achievement orientation
Number of subjects: 11153

Group type: EXPERIMENTAL
Intervention: Family medical history
Number of subjects: 11153

Group type: EXPERIMENTAL
Intervention: Gender, age, and dwelling differences
Number of subjects: 11153
Study: 28603225

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Topiroxostat
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 55
Study: 25828671

Group type: EXPERIMENTAL
Intervention: Pre-hospital predictors of death or cardiovascular complications during hospitalisation
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Pre-hospital predictors of all-cause death during one year of follow-up
Number of subjects: 1600
Study: 23512255

Group type: EXPERIMENTAL
Intervention: New design implant
Number of subjects: 212

Group type: COMPARATOR
Intervention: Traditional implant
Number of subjects: 212
Study: 20962502

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 64
Study: 18086024

Group type: EXPERIMENTAL
Intervention: Probiotic lozenge with L. reuteri ATCC 55730/L. reuteri ATCC PTA 5289 (1.1 x 10(8) CFU) once daily for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo medical devices without bacteria
Number of subjects: 20
Study: 16615716

Group type: COMPARATOR
Intervention: Merely Recognized (MR) vs. Unrecognized (UR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recognized with Knowledge (RK) vs. Unrecognized (UR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender Comparison
Number of subjects: 0
Study: 14631217

Group type: EXPERIMENTAL
Intervention: Neck anastomosis
Number of subjects: 83

Group type: COMPARATOR
Intervention: Chest anastomosis
Number of subjects: 83
Study: 10939996

Group type: EXPERIMENTAL
Intervention: Clinical opinion leaders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guideline implementation programs
Number of subjects: 0
Study: 9093740

Group type: EXPERIMENTAL
Intervention: Music intervention during the last 30 minutes of surgery and the first hour in PACU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with identical surgical procedures and anesthesia protocol without music
Number of subjects: 0
Study: 8462010

Group type: EXPERIMENTAL
Intervention: Epidoxorubicin 60 mg/m2 (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidoxorubicin 120 mg/m2 (group B)
Number of subjects: 50
Study: 2941697

Group type: EXPERIMENTAL
Intervention: Phenoterol administered after ipratropium bromide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ipratropium bromide administered before phenoterol
Number of subjects: 18
Study: 31671251

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 1:100,000 epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline infiltration
Number of subjects: 40
Study: 29891834

Group type: EXPERIMENTAL
Intervention: Reduced-dose tacrolimus (4.51±1.62 ng/mL)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Standard tacrolimus dosage (6.75±2.82 ng/mL)
Number of subjects: 345
Study: 27399077

Group type: EXPERIMENTAL
Intervention: EBV DNA detected in breast milk
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: EBV DNA levels in SCM and possible SCM
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: EBV DNA level >200 copies/mL
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Higher EBV replication in SCM
Number of subjects: 83
Study: 24504441

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 21999492

Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd:YAG laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 50
Study: 20706732

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (300 unilateral, maximal, isokinetic, eccentric contractions at 30° s(‐1))
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (Ecc)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Concentric action (Con)
Number of subjects: 6
Study: 18797304

Group type: EXPERIMENTAL
Intervention: Lag-2 sparing (T2 followed by a third target)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lag-1 sparing (T2 appears directly after T1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P3 component of event-related potential
Number of subjects: 0
Study: 16189173

Group type: EXPERIMENTAL
Intervention: 500 ml 5% glucose solution infused over 30 min after achieving hypoglycemia
Number of subjects: 16

Group type: COMPARATOR
Intervention: 500 ml isotonic saline infused over 30 min after achieving hypoglycemia
Number of subjects: 16
Study: 12651646

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 50
Study: 10657578

Group type: EXPERIMENTAL
Intervention: HMG‐CoA reductase inhibitors in FH patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fibrates in HTG patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normolipidemic controls
Number of subjects: 23
Study: 8866634

Group type: EXPERIMENTAL
Intervention: Brofaromine 75 mg
Number of subjects: 24
Study: 1593512

Group type: EXPERIMENTAL
Intervention: Friend present‐touch (FT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Friend present‐no touch (FNT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stranger present‐touch (ST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stranger present‐no touch (SNT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alone (A)
Number of subjects: 60
Study: 6741679

Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes (2.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium nicotine cigarettes (1.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low nicotine cigarettes (0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Condition with olfactory stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Condition with blocked olfaction
Number of subjects: 0
Study: 30659074

Group type: EXPERIMENTAL
Intervention: Genetically increased A1C
Number of subjects: 159940

Group type: EXPERIMENTAL
Intervention: Higher A1C using glycemic variants
Number of subjects: 159940

Group type: EXPERIMENTAL
Intervention: Higher A1C using erythrocytic variants
Number of subjects: 159940

Group type: EXPERIMENTAL
Intervention: Genetically decreased Hb
Number of subjects: 159940
Study: 29923286

Group type: EXPERIMENTAL
Intervention: PF-06291874 (30 mg once daily)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: PF-06291874 (60 mg once daily)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: PF-06291874 (100 mg once daily)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: PF-06291874 (30, 60, or 100 mg once daily)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: PF-06291874
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 27661415

Group type: EXPERIMENTAL
Intervention: Ivabradine 5mg twice a day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 32
Study: 24264372

Group type: EXPERIMENTAL
Intervention: Ibandronate (cumulative dose, 13.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 30
Study: 22398753

Group type: EXPERIMENTAL
Intervention: Spread containing bioactive milk peptides IPP and VPP, and plant sterols (20 g day⁻¹ for 10 weeks)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 19815048

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (Ginko T.D. Tolidaru, Iran) at a dose of 80‐120 mg/day depending on weight (80 mg/day for <30 kg and 120 mg/day for >30 kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methylphenidate at a dose of 20‐30 mg/day depending on weight (20 mg/day for <30 kg and 30 mg/day for >30 kg)
Number of subjects: 50
Study: 17506152

Group type: EXPERIMENTAL
Intervention: Persistent pain
Number of subjects: 397
Study: 15642027

Group type: EXPERIMENTAL
Intervention: Overdenture supported by two IMZ implants (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overdenture supported by four IMZ implants (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 60
Study: 11920996

Group type: EXPERIMENTAL
Intervention: Muscular images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral advertisements
Number of subjects: 0
Study: 9863280

Group type: EXPERIMENTAL
Intervention: Pityrosporum found in extracted follicular material
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bacteria found in extracted follicular material
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Histologic examination of biopsied specimens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bacterial culture
Number of subjects: 30
Study: 7605755

Group type: EXPERIMENTAL
Intervention: Nerve stimulator technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fan technique
Number of subjects: 40
Study: 10109801

Group type: EXPERIMENTAL
Intervention: EuroQol instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual analogue scale
Number of subjects: 0
Study: 378574

Group type: EXPERIMENTAL
Intervention: Rifampicin-trimethoprim combination (450 mg plus 120 mg twice daily)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Rifampicin alone (450 mg twice daily)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Rifampicin-trimethoprim combination and rifampicin alone
Number of subjects: 146
Study: 30906562

Group type: EXPERIMENTAL
Intervention: 200 mg Nilotinib
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 28323799

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (PO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous antibiotics (IV)
Number of subjects: 0
Study: 25539239

Group type: EXPERIMENTAL
Intervention: 5 min-FA30
Number of subjects: 116

Group type: COMPARATOR
Intervention: 20 min-FA10
Number of subjects: 116
Study: 23928716

Group type: EXPERIMENTAL
Intervention: Rehabilitation initiated at 6 weeks after surgery
Number of subjects: 82

Group type: COMPARATOR
Intervention: Rehabilitation initiated at 12 weeks after surgery
Number of subjects: 82
Study: 21669016

Group type: EXPERIMENTAL
Intervention: Intranasal steroid plus per-oral vitamins A, C and E and selenium
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intranasal steroid
Number of subjects: 34
Study: 19155904

Group type: EXPERIMENTAL
Intervention: 1-day nitrofurantoin regimen (100 mg capsules, taken twice daily for 1 day)
Number of subjects: 778

Group type: COMPARATOR
Intervention: 7-day nitrofurantoin regimen (100 mg capsules, taken twice daily for 7 days)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: 1-day nitrofurantoin regimen
Number of subjects: 778
Study: 16716870

Group type: EXPERIMENTAL
Intervention: Ziconotide (0.1 microg/hour starting dose, titrated to a mean dose of 0.29 microg/hour)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ziconotide
Number of subjects: 220
Study: 14757690

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 96

Group type: COMPARATOR
Intervention: no abciximab
Number of subjects: 96
Study: 11571009

Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with viral load decrease
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with viral load increase
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with no change in viral load
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with medication change recommended
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Medical feedback vignette with no medication change recommended
Number of subjects: 207
Study: 9713464

Group type: EXPERIMENTAL
Intervention: GRA 1 mg + DEX 20 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: GRA 3 mg + DEX 20 mg
Number of subjects: 198
Study: 7871376

Group type: EXPERIMENTAL
Intervention: Breath test after magnesium application
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intubation test
Number of subjects: 10
Study: 3259413

Group type: EXPERIMENTAL
Intervention: Cimetidine (H2 antagonist)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40